No annual revenue total was found in Cingulate Inc.'s SEC filings.
Cingulate Inc. (CING) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$17.4 million. As of Jun 30, 2026 it held $28.4 million in cash and investments and $1.2 million in total debt.
Revenue
—
Net income (TTM)
$-28.80M
-49.9% vs year-ago TTM
Operating cash flow (TTM)
$-20.65M
-18.9% vs year-ago TTM
Free cash flow (TTM)
$-20.94M
-20.1% vs year-ago TTM
EPS (TTM)
$-3.29
+44.0% vs year-ago TTM
Dividend per share
None
Shares outstanding
11.63M
+208.6% vs prior year
Net cash
$27.18M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CING (Nasdaq), CINGW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Kansas City, KS
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1862150
- Former names
- Cingulate Inc. (until Oct 2, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$19.9M | -$15.6M | -$22.8M | -$17.5M | -$20.7M |
| Net income | -$22.4M | -$16.6M | -$23.5M | -$17.7M | -$20.7M |
| Diluted EPS | -$4.44 | -$10.86 | -$311.99 | — | — |
| Operating cash flow | -$17.2M | -$18.5M | -$15.0M | -$15.9M | -$10.4M |
| Free cash flow | -$17.4M | -$18.7M | -$15.3M | -$16.0M | -$11.2M |
| Total assets | $15.1M | $14.9M | $3.5M | $11.4M | $22.9M |
| Total liabilities | $12.6M | $7.4M | $10.4M | $7.5M | $2.0M |
| Stockholders' equity | $2.5M | $7.5M | -$6.9M | $3.9M | $20.8M |
| Cash and investments | $11.0M | $12.2M | $52,416 | $5.4M | $16.5M |
| Total debt | $1.3M | $135,092 | $510,241 | $866,043 | $1.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Oct 2, 2026 | Sep 30, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 23, 2026 | Jul 17, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jul 14, 2026 | Jul 9, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jul 2, 2026 | Jun 30, 2026 |
All 493 Cingulate Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.